LYMTAC-2 is a lysosomal-targeting chimera (LYMTAC) designed to degrade membrane-associated proteins by leveraging lysosomal membrane proteins (LMPs) like RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with its target protein, such as KRASG12D, and facilitates relocalization to the lysosome, leading to ubiquitin-dependent degradation. It has the potential to study membrane protein regulation and develop […]

LYMTAC-2 is a lysosomal-targeting chimera (LYMTAC) designed to degrade membrane-associated proteins by leveraging lysosomal membrane proteins (LMPs) like RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with its target protein, such as KRASG12D, and facilitates relocalization to the lysosome, leading to ubiquitin-dependent degradation. It has the potential to study membrane protein regulation and develop […]

LYMTAC-2 is a lysosomal-targeting chimera (LYMTAC) designed to degrade membrane-associated proteins by leveraging lysosomal membrane proteins (LMPs) like RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with its target protein, such as KRASG12D, and facilitates relocalization to the lysosome, leading to ubiquitin-dependent degradation. It has the potential to study membrane protein regulation and develop […]

Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.

Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.

Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.

COH34 is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with an IC50 value of 0.37 nM. It binds to the catalytic domain of PARG with Kd of 0.547 μM thereby prolonging PARylation at DNA lesions and trapping DNA repair factors and can be used in research of cancer therapies.

Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.

COH34 is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with an IC50 value of 0.37 nM. It binds to the catalytic domain of PARG with Kd of 0.547 μM thereby prolonging PARylation at DNA lesions and trapping DNA repair factors and can be used in research of cancer therapies.

COH34 is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with an IC50 value of 0.37 nM. It binds to the catalytic domain of PARG with Kd of 0.547 μM thereby prolonging PARylation at DNA lesions and trapping DNA repair factors and can be used in research of cancer therapies.